Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 9/20 | 0.44 |
| ▸ | F2 | P00734 | 5/20 | 0.44 |
| ▸ | PLAU | P00749 | 5/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 5/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.37 |
| ▸ | F2R | P25116 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27730187 | 0.91 | ELANE (0.43) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL2922296 | 0.91 | ELANE (0.41) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL1457094 | 0.85 | ELANE (0.47) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL29508910 | 0.85 | ELANE (0.47) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL29508852 | 0.85 | ELANE (0.47) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL2861095 | 0.85 | ELANE (0.50) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL2144637 | 0.84 | ELANE (0.47) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL30123629 | 0.84 | ELANE (0.47) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL2573606 | 0.83 | ELANE (0.47) | ELANEF2PLAUCTRB1KLKB1 | |
| SCHEMBL1456636 | 0.83 | ELANE (0.47) | ELANEF2PLAUCTRB1KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| EP-1966151-B1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORP (US) | 2011-10-05 | — | — | EP | disclosed |
| EP-1966151-B1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORP (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010046780-A2 | ANTI VIRAL COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2010-04-29 | — | — | WO | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | SCHERING CORPORATION | 2007-08-16 | — | — | US | disclosed |
| WO-2007070398-A1 | POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPK10 | ELANE 3367/4885F2 4355/4885PLAU 4280/4885 |
| US-20070191604-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPKAPK2 | ELANE 3980/4885F2 4067/4885PLAU 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.